Repeated S‐ketamine Infusions in Therapy Resistant Depression: A Case Series

Segmiller, Felix; Rüther, Tobias; Linhardt, A.; Padberg, Frank; Berger, Michael; Pogarell, Oliver; Möller, Hans‐Jürgen; Köhler, Christof; Schüle, Cornelius

doi:10.1002/jcph.122

Cited by 60 publications

(31 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Published open-label case reports suggest that repeated ketamine infusions may safely extend the benefits of ketamine for several months (18), and unpublished clinical observations suggest that these benefits may be extended for a year or more (19). The limited pilot data currently available are consistent with this view in suggesting that up to six infusions of low-dose ketamine administered once, twice, or three times per week are efficacious in maintaining and prolonging treatment response (20–24). A larger controlled study of repeated ketamine administration was recently completed (NCT01627782), and the results will be available in the coming months.…”

Section: The Rapid Antidepressant Effects Of Ketaminementioning

confidence: 78%

Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics

et al. 2015

View full text Add to dashboard Cite

Ketamine is the prototype for a new generation of glutamate-based antidepressants that rapidly alleviate depression within hours of treatment. Over the past decade, there has been replicated evidence demonstrating the rapid and potent antidepressant effects of ketamine in treatment-resistant depression. Moreover, preclinical and biomarker studies have begun to elucidate the mechanism underlying the rapid antidepressant effects of ketamine, offering a new window into the biology of depression and identifying a plethora of potential treatment targets. This article discusses the efficacy, safety, and tolerability of ketamine, summarizes the neurobiology of depression, reviews the mechanisms underlying the rapid antidepressant effects of ketamine, and discusses the prospects for next-generation rapid-acting antidepressants.

show abstract

Section: The Rapid Antidepressant Effects Of Ketaminementioning

confidence: 78%

Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Recent reports on its use in treatment of refractory depressive symptoms have been explored in a case series of 6 patients with promising results. 18 A randomized, double-blind crossover study similarly found promising results in treatment of obsessive-compulsive disorder. 19 Within the field of headache medicine, a double-blind, randomized controlled study has shown benefit of intranasal ketamine in reducing the severity of aura in patients with migraine with prolonged aura.…”

Section: Discussionmentioning

confidence: 99%

Ketamine Infusions for Treatment Refractory Headache

et al. 2016

View full text Add to dashboard Cite

show abstract

“…While chronic treatment with ketamine has been reported to prolong the antidepressant response [24–28], considering potential risk of addiction, we did not continue to administer ketamine repeatedly. In few clinical trails, ketamine-treated patients experienced transient hemodynamic effects [29–33], which indicates strict patient monitoring is needed in future studies.…”

Section: Discussionmentioning

confidence: 99%

Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial

Fan

H²,

Sun

et al. 2016

Oncotarget

View full text Add to dashboard Cite

This study was designed to examine the rapid antidepressant effects of single dose ketamine on suicidal ideation and overall depression level in patients with newly-diagnosed cancer. Forty-two patients were enrolled into the controlled trial and randomized into two groups: ketamine group and midazolam group. Patients from the two groups received a sub-anesthetic dose of racemic ketamine hydrochloride or midazolam. Suicidal ideation score, measured with the Beck Scale and suicidal part of the Montgomery-Asberg Depression Rating Scale, significantly decreased on day 1 and day 3 in ketamine-treated patients when compared to those treated with midazolam. Consistently, overall depression levels measured using the Montgomery-Asberg Depression Rating Scale indicated a significant relief of overall depression on day 1 in ketamine-treated patients. Collectively, this study provides novel information about the rapid antidepressant effect of ketamine on acute depression and suicidal ideation in newly-diagnosed cancer patients.

show abstract

Repeated S‐ketamine Infusions in Therapy Resistant Depression: A Case Series

Cited by 60 publications

References 8 publications

Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics

Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics

Ketamine Infusions for Treatment Refractory Headache

Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial

Contact Info

Product

Resources

About